EyePoint Pharmaceuticals, Inc. (EYPT) vs Greenwich LifeSciences, Inc. (GLSI)
A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and Greenwich LifeSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EYPT
EyePoint Pharmaceuticals, Inc.
$3.08HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
GLSI
Greenwich LifeSciences, Inc.
$16.60HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — EYPT vs GLSI
growth of $100 · dividends reinvested · last 6yEYPT -40.6% (-8.3%/yr)GLSI +238.2% (+22.5%/yr)GLSI compounded faster over this window
Log scale — wide-divergence pair
EYPT GLSI
EYPT vs GLSI: by the numbers
- •EYPT is the larger company ($258M vs $244M market cap).
- •Both run net losses; GLSI's is the smaller (0.00% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | EYPT | GLSI |
|---|---|---|
| P/S ratio | 92.68 | N/A |
| P/B ratio | 1.55 | 78.16 |
Profitability
| Metric | EYPT | GLSI |
|---|---|---|
| Gross margin | 93.41% | 0.00% |
| Operating margin | -775.98% | 0.00% |
| Net margin | -10994.73% | 0.00% |
| ROE | -184.27% | -695.56% |
| ROIC | -170.19% | -701.55% |
Growth (annualized)
| Metric | EYPT | GLSI |
|---|---|---|
| Revenue CAGR (5Y) | -41.05% | N/A |
| Total return CAGR (5Y) | -21.68% | -14.84% |
Frequently asked
- How have EYPT and GLSI total returns compared?
- Over the past 5 years, EYPT delivered -21.68% and GLSI delivered -14.84% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.